National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report
复制标题
DOI：
10.1016/j.bbmt.2016.08.019
复制
发表时间：
2017-02-01
影响因子：
4.3
通讯作者：
Battiwalla, Minoo
中科院分区：
文献类型：
--
作者：
Armenian, Saro H.;Chemaitilly, Wassim;Battiwalla, Minoo
许多研究表明，自体和同种异体造血细胞移植（HCT）导致心血管疾病（CVD）的发病率增加，心血管风险因素恶化，随着时间的推移，可能导致进一步的CVD。这些观察结果，结合近年来HCT后存活者数量的显着增加，强调了通过改变特定方法和/或HCT后干预来改变风险或预防这些结局的研究的必要性。为了解决这些问题，国家心脏，肺和血液研究所和国家癌症研究所共同发起了一项关于HCT后迟发效应的国际倡议。本报告总结了知识的主要差距，沿着来自心血管疾病和相关风险因素委员会（一个多学科的国际专家小组）的关于研究优先级的详细建议。该委员会呼吁开展旨在了解和预防动脉疾病和心功能障碍（心力衰竭，瓣膜病和心律失常）以及降低HCT后心血管危险因素（高血压，高血糖，血脂异常和肌肉减少性肥胖）的具体研究。(C)2017年美国血液和骨髓移植协会。爱思唯尔公司出版All rights reserved.
A number of studies have shown that autologous and allogeneic hematopoietic cell transplantation (HCT) contribute to an increased incidence of cardiovascular disease (CVD) and worsening of cardiovascular risk factors that could contribute to further CVD over time. These observations, combined with a notable increase in the number of survivors after HCT in recent years, highlight the need for studies aimed at modifying risk or preventing these outcomes by changing specific approaches and/or post-HCT interventions. To address these issues, the National Heart, Lung and Blood Institute and National Cancer Institute co-sponsored an international initiative on late effects after HCT. This report summarizes the major gaps in knowledge along with detailed recommendations regarding study priorities from the Cardiovascular Disease and Associated Risk Factors Committee, a multidisciplinary panel of international experts. The committee calls for specific studies aimed at understanding and preventing arterial disease and cardiac dysfunction (heart failure, valvular disease, and arrhythmias), as well as decreasing cardiovascular risk factors (hypertension, hyperglycemia, dyslipidemia, and sarcopenic obesity) after HCT. (C) 2017 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.